Alpha 2.0
Login Register
» Authors » Julie E Hallanger-Johnson

Julie E Hallanger-Johnson

Explore the profile of Julie E Hallanger-Johnson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 101
Followers 0
Related Specialties
Oncology
General Surgery
Endocrinology
Top 10 Co-Authors
Pablo Valderrabano
Bryan McIver
Zachary J Thompson
Kristen J Otto
Laila Khazai
Christine H Chung
Barbara A Centeno
Marino E Leon
J Trad Wadsworth
Bruce M Wenig
Published In
JAMA Otolaryngol Head Neck Surg
Thyroid
Endocr Relat Cancer
Head Neck
Affiliations
Soon will be listed here.
Recent Articles
1.
Comparison of Postmarketing Findings vs the Initial Clinical Validation Findings of a Thyroid Nodule Gene Expression Classifier: A Systematic Review and Meta-analysis
Valderrabano P, Hallanger-Johnson J, Thapa R, Wang X, McIver B
JAMA Otolaryngol Head Neck Surg . 2019 Jul; 145(9):783-792. PMID: 31318389
Importance: In the United States, the most used molecular test for the evaluation of cytologically indeterminate thyroid nodules is the Afirma gene expression classifier (GEC). Objective: To evaluate the GEC's...
2.
Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid Nodules
Valderrabano P, Khazai L, Thompson Z, Otto K, Hallanger-Johnson J, Chung C, et al.
JAMA Otolaryngol Head Neck Surg . 2018 Jul; 144(9):788-795. PMID: 30027226
Importance: Tens of thousands of unnecessary operations are performed each year for diagnostic purposes among patients with cytologically indeterminate thyroid nodules. Whereas a diagnostic lobectomy is recommended for most patients...
3.
Impact of oncogene panel results on surgical management of cytologically indeterminate thyroid nodules
Valderrabano P, Khazai L, Thompson Z, Leon M, Otto K, Hallanger-Johnson J, et al.
Head Neck . 2018 Apr; 40(8):1812-1823. PMID: 29624786
Background: The impact of oncogene panel results on the surgical management of indeterminate thyroid nodules (ITNs) is currently unknown. Methods: Surgical management of 649 patients consecutively evaluated from October 2008...
4.
Cancer Risk Associated with Nuclear Atypia in Cytologically Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis
Valderrabano P, Khazai L, Thompson Z, Sharpe S, Tarasova V, Otto K, et al.
Thyroid . 2017 Nov; 28(2):210-219. PMID: 29160163
Background: Indeterminate categories of thyroid cytopathology (categories B-III and B-IV of the Bethesda system) are integrated by a heterogeneous spectrum of cytological scenarios that are generally clustered for analysis and...
5.
Cancer Risk Stratification of Indeterminate Thyroid Nodules: A Cytological Approach
Valderrabano P, Khazai L, Thompson Z, Leon M, Otto K, Hallanger-Johnson J, et al.
Thyroid . 2017 Aug; 27(10):1277-1284. PMID: 28806881
Background: Management recommendations for thyroid nodules rely primarily on the cytological diagnosis. However, 25% of biopsies render an indeterminate cytology for which management decision is more challenging due to heterogeneity...
6.
Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology
Valderrabano P, Khazai L, Leon M, Thompson Z, Ma Z, Chung C, et al.
Endocr Relat Cancer . 2017 Jan; 24(3):127-136. PMID: 28104680
ThyroSeq v2 claims high positive (PPV) and negative (NPV) predictive values in a wide range of pretest risks of malignancy in indeterminate thyroid nodules (ITNs) (categories B-III and B-IV of...